Compassionate Use of Dupilumab

Sponsor: Regeneron Pharmaceuticals
Study ID: NCT04776694
Status: Approved For Marketing

Conditions

Type 2 Inflammatory Disorders

Eligibility Criteria

Sex: All
Age: N/A - N/A
Healthy Volunteers: Not accepted

Interventions

Dupilumab — DRUG

Study Details

Provide Compassionate Use of Dupilumab

Key Dates

Status verified: Sep 2025